Xenova Group plc with Successful Results from Second Clinical Trial of Anti-Smoking Vaccine, TA-NIC
15-Jul-2004 -
Slough, UK. Xenova Group plc announced initial results from the second clinical trial of TA-NIC, the Company's therapeutic vaccine being developed for the treatment of nicotine addiction.
60 smokers, divided into three cohorts of 20 subjects, have been recruited into this double-blind, ...
addiction
antibodies
clinical trials
+1